|
.Folkman, J. et al. Angiogenesis. J. Biol. Chem. 267, 16, 10931-10934(1992) 2.Folkman, J. Tumor angiogenesis: Therapeutic implications. New Engl. J. Med.285, 1182-1186(1971) 3. Folkman, J. What is the evidence that tumors are angiogenesis dependent? Journal of the National Cancer Institute 82,1(1990) 4. Brower, V. Tumor angiogenesis- new drugs on the block. Nature Biotechnology 17, 963-958(1999) 5. Folkman, J. et al. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364(1996) 6. Hayes, A. J. et al. Science, medicine, and the future. Antivascular therapy: a new approach to cancer treatment. BMJ 318, 853-856(1999) 7. Hanahan, D. et al. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-264(1996) 8. Weidner, N. Current pathological methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res. Treat. 36, 169-180(1996) 9. Esch, F., et al. Primary structure of bovine pituitary basic fibroblast growth factor(FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF. Proc. Natl. Acad. Sci. USA 82, 6507-6511(1985) 10.Ferrara, N. et al. Endocr. Rev. 13, 15-32(1992) 11.Good, D. J. et al. Proc. Natl. Acad. Sci. USA 87, 6624-6628 (1990) 12. Kim, K. et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362, 841-844(1993) 13. Klohs, W. D. et al. Antiangiogenic agents. Current Opinion in Biotechnology 10, 544-549(1999) 14. Folkman, J. Suppression of hematopoiesis and gastrointestinal symptoms. N. Engl. J. Med. 333, 1757-1763(1995) 15.Cao, Y., et al. Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells. J. Bio. Chem. 271, 29461-29467(1996) 16. Folkman, J. et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis Lung carcinoma. Cell 79,315-328 (1994) 17. Sottrup-Jensen, L. et al. The primary structure of human plasminogen: isolation of two lysine-binding fragments and one “mini”-plasminogen by elastase-catalyzed-specific limited proteolysis. Progress in Chemical Fibrinolysis and Thrombolysis. 191-209(1978) 18. Sim, B. et al. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Research 57, 1329-1334 (1997) 19. O’Reilly, M.S. et al. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 2, 689-692 (1996) 20. Dong, Z. et al. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 88, 801-810(1997) 21. Patterson, B. C. et al. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collogenase(MMP-9). J. Biol. Chem. 272, 46, 28823-28825(1997) 22.Gately, S. et al. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Research 56, 4887-4890 (1996) 23. Gately, S. et al. Proc. Natl. Acad. Sci. USA 94,10868-10872(1997) 24. Lu, H. et al. Kringle 5 causes cell cycle arrest and apoptosis of endothelial cells. Biochem. Biophys. Res. Commun. 258, 668-673(1999) 25.Urlaub, G. et al. Isolation of Chinese hamster cell mutants deficient in dihydrofoalte reductase activity. Proc. Natl. Acad. Sci. USA 77, 4216-4220(1980) 26. Wurm, F. M. Integration, amplification and stability of plasmid sequence in CHO cell cultures. Biologicals 18, 159-164(1990) 27. Wiman, B. et al. Molecular mechanism of physiological fibrinolysis. Nature 272, 549-550(1978) 28. Marti, N. D. et al. Ligand preferences of kringle 2 and homologous domains of human plasminogen: canvassing weak, intermediate, and high-affinity binding sites by 1H-NMR. Biochemistry 36, 11591-11604(1997) 29. Hayes, M. L. et al. J. Biol. Chem. 254, 8768-8780(1979) 30.Collen, D. On the regulation and control of fibrinolysis. Thromb. Haemost. 43, 77(1980) 31. Folkman, J. Long-term culture of capillary endothelial cells. Proc. Natl. Acad. Sci. USA 76. 10, 5217-5221 (1979) 32. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods 65, 55-63 (1983) 33. Slater, T. F., et al. Biochem. Biophys. Acta. 77, 383 (1963) 34. Kenyon, B. M., et al. A Model of angiogenesis in the mouse cornea. Invest. Ophthalmol Vis. Sci. 37, 1625-1632 (1996) 35. Weidong-Richard, JI. et al. Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis. FASEB J. 12, 1731-1738(1998) 36. MacDonald, N. J. et al. The tumor-suppressing activity of angiostatin protein resides within kringles 1-3. Biochem. Biophys. Res. Commun. 264, 469-477(1999) 37. Clement, B. et al. Homeostatic control of angiogenesis: a newly identified function of the liver? Hepatology 29, 3, 621-623(1999) 38. Griscelli, F. et al. Proc. Natl. Acad. Sci. USA 95, 6367-6372 (1998) 39.Claesson-Welsh, L. et al. Proc. Natl. Acad. Sci. USA 95, 5579-5583 (1998) 40. Moser, T. L. et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc. Natl. Acad. Sci. USA 96, 2811-2816 (1999)
|